Literature DB >> 27574109

Analysis of isoform-specific tau aggregates suggests a common toxic mechanism involving similar pathological conformations and axonal transport inhibition.

Kristine Cox1, Benjamin Combs2, Brenda Abdelmesih3, Gerardo Morfini4, Scott T Brady5, Nicholas M Kanaan6.   

Abstract

Misfolded tau proteins are characteristic of tauopathies, but the isoform composition of tau inclusions varies by tauopathy. Using aggregates of the longest tau isoform (containing 4 microtubule-binding repeats and 4-repeat tau), we recently described a direct mechanism of toxicity that involves exposure of the N-terminal phosphatase-activating domain (PAD) in tau, which triggers a signaling pathway that disrupts axonal transport. However, the impact of aggregation on PAD exposure for other tau isoforms was unexplored. Here, results from immunochemical assays indicate that aggregation-induced increases in PAD exposure and oligomerization are common features among all tau isoforms. The extent of PAD exposure and oligomerization was larger for tau aggregates composed of 4-repeat isoforms compared with those made of 3-repeat isoforms. Most important, aggregates of all isoforms exhibited enough PAD exposure to significantly impair axonal transport in the squid axoplasm. We also show that PAD exposure and oligomerization represent common pathological characteristics in multiple tauopathies. Collectively, these results suggest a mechanism of toxicity common to each tau isoform that likely contributes to degeneration in different tauopathies.
Copyright © 2016 The Author(s). Published by Elsevier Inc. All rights reserved.

Entities:  

Keywords:  Aggregation; Alzheimer's disease; Axon; Microtubule-associated protein; Oligomer; Pathological conformations; Tauopathy

Mesh:

Substances:

Year:  2016        PMID: 27574109      PMCID: PMC5075521          DOI: 10.1016/j.neurobiolaging.2016.07.015

Source DB:  PubMed          Journal:  Neurobiol Aging        ISSN: 0197-4580            Impact factor:   4.673


  90 in total

1.  Alz-50 and MC-1, a new monoclonal antibody raised to paired helical filaments, recognize conformational epitopes on recombinant tau.

Authors:  G A Jicha; R Bowser; I G Kazam; P Davies
Journal:  J Neurosci Res       Date:  1997-04-15       Impact factor: 4.164

2.  Tau Oligomers Derived from Traumatic Brain Injury Cause Cognitive Impairment and Accelerate Onset of Pathology in Htau Mice.

Authors:  Julia Gerson; Diana L Castillo-Carranza; Urmi Sengupta; Riddhi Bodani; Donald S Prough; Douglas S DeWitt; Bridget E Hawkins; Rakez Kayed
Journal:  J Neurotrauma       Date:  2016-04-22       Impact factor: 5.269

3.  The amino terminus of tau inhibits kinesin-dependent axonal transport: implications for filament toxicity.

Authors:  Nichole E LaPointe; Gerardo Morfini; Gustavo Pigino; Irina N Gaisina; Alan P Kozikowski; Lester I Binder; Scott T Brady
Journal:  J Neurosci Res       Date:  2009-02       Impact factor: 4.164

4.  Pathogenic forms of tau inhibit kinesin-dependent axonal transport through a mechanism involving activation of axonal phosphotransferases.

Authors:  Nicholas M Kanaan; Gerardo A Morfini; Nichole E LaPointe; Gustavo F Pigino; Kristina R Patterson; Yuyu Song; Athena Andreadis; Yifan Fu; Scott T Brady; Lester I Binder
Journal:  J Neurosci       Date:  2011-07-06       Impact factor: 6.167

Review 5.  Tau oligomers and tau toxicity in neurodegenerative disease.

Authors:  Sarah M Ward; Diana S Himmelstein; Jody K Lancia; Lester I Binder
Journal:  Biochem Soc Trans       Date:  2012-08       Impact factor: 5.407

6.  Characterization of prefibrillar Tau oligomers in vitro and in Alzheimer disease.

Authors:  Kristina R Patterson; Christine Remmers; Yifan Fu; Sarah Brooker; Nicholas M Kanaan; Laurel Vana; Sarah Ward; Juan F Reyes; Keith Philibert; Marc J Glucksman; Lester I Binder
Journal:  J Biol Chem       Date:  2011-05-06       Impact factor: 5.157

7.  Identification of oligomers at early stages of tau aggregation in Alzheimer's disease.

Authors:  Cristian A Lasagna-Reeves; Diana L Castillo-Carranza; Urmi Sengupta; Jose Sarmiento; Juan Troncoso; George R Jackson; Rakez Kayed
Journal:  FASEB J       Date:  2012-01-17       Impact factor: 5.191

8.  Phosphorylation, calpain proteolysis and tubulin binding of recombinant human tau isoforms.

Authors:  J M Litersky; C W Scott; G V Johnson
Journal:  Brain Res       Date:  1993-02-26       Impact factor: 3.252

9.  Staging of Alzheimer disease-associated neurofibrillary pathology using paraffin sections and immunocytochemistry.

Authors:  Heiko Braak; Irina Alafuzoff; Thomas Arzberger; Hans Kretzschmar; Kelly Del Tredici
Journal:  Acta Neuropathol       Date:  2006-08-12       Impact factor: 17.088

10.  Internalized Tau Oligomers Cause Neurodegeneration by Inducing Accumulation of Pathogenic Tau in Human Neurons Derived from Induced Pluripotent Stem Cells.

Authors:  Marija Usenovic; Shahriar Niroomand; Robert E Drolet; Lihang Yao; Renee C Gaspar; Nathan G Hatcher; Joel Schachter; John J Renger; Sophie Parmentier-Batteur
Journal:  J Neurosci       Date:  2015-10-21       Impact factor: 6.167

View more
  23 in total

Review 1.  Amyloidogenesis of Tau protein.

Authors:  Bartosz Nizynski; Wojciech Dzwolak; Krzysztof Nieznanski
Journal:  Protein Sci       Date:  2017-09-13       Impact factor: 6.725

2.  T-complex protein 1-ring complex enhances retrograde axonal transport by modulating tau phosphorylation.

Authors:  Xu-Qiao Chen; Fang Fang; Jazmin B Florio; Edward Rockenstein; Eliezer Masliah; William C Mobley; Robert A Rissman; Chengbiao Wu
Journal:  Traffic       Date:  2018-09-12       Impact factor: 6.215

3.  Tau accumulation triggers STAT1-dependent memory deficits by suppressing NMDA receptor expression.

Authors:  Xiao-Guang Li; Xiao-Yue Hong; Ya-Li Wang; Shu-Juan Zhang; Jun-Fei Zhang; Xia-Chun Li; Yan-Chao Liu; Dong-Shen Sun; Qiong Feng; Jin-Wang Ye; Yuan Gao; Dan Ke; Qun Wang; Hong-Lian Li; Keqiang Ye; Gong-Ping Liu; Jian-Zhi Wang
Journal:  EMBO Rep       Date:  2019-05-13       Impact factor: 8.807

Review 4.  Roles of tau protein in health and disease.

Authors:  Tong Guo; Wendy Noble; Diane P Hanger
Journal:  Acta Neuropathol       Date:  2017-04-06       Impact factor: 17.088

5.  The role of wild-type tau in Alzheimer's disease and related tauopathies.

Authors:  Chih Hung Lo; Jonathan N Sachs
Journal:  J Life Sci (Westlake Village)       Date:  2020-12

6.  Exposure of the Amino Terminus of Tau Is a Pathological Event in Multiple Tauopathies.

Authors:  Benjamin Combs; Nicholas M Kanaan
Journal:  Am J Pathol       Date:  2017-04-14       Impact factor: 4.307

Review 7.  Regulation of motor proteins, axonal transport deficits and adult-onset neurodegenerative diseases.

Authors:  Scott T Brady; Gerardo A Morfini
Journal:  Neurobiol Dis       Date:  2017-04-11       Impact factor: 5.996

8.  Tau and Axonal Transport Misregulation in Tauopathies.

Authors:  Benjamin Combs; Rebecca L Mueller; Gerardo Morfini; Scott T Brady; Nicholas M Kanaan
Journal:  Adv Exp Med Biol       Date:  2019       Impact factor: 2.622

9.  Production of recombinant tau oligomers in vitro.

Authors:  Benjamin Combs; Chelsea T Tiernan; Chelsey Hamel; Nicholas M Kanaan
Journal:  Methods Cell Biol       Date:  2017-07-14       Impact factor: 1.441

10.  Tau is not necessary for amyloid-β-induced synaptic and memory impairments.

Authors:  Daniela Puzzo; Elentina K Argyrousi; Agnieszka Staniszewski; Hong Zhang; Elisa Calcagno; Elisa Zuccarello; Erica Acquarone; Mauro Fa'; Domenica D Li Puma; Claudio Grassi; Luciano D'Adamio; Nicholas M Kanaan; Paul E Fraser; Ottavio Arancio
Journal:  J Clin Invest       Date:  2020-09-01       Impact factor: 14.808

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.